Citigroup Has Lowered Expectations for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its target price lowered by research analysts at Citigroup from $88.00 to $87.00 in a report released on Friday,Benzinga reports. The firm currently has a “neutral” rating on the medical device company’s stock. Citigroup’s price objective would indicate a potential upside of 12.32% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company upped their price target on Cooper Companies from $72.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, December 5th. The Goldman Sachs Group reissued a “sell” rating and set a $73.00 target price on shares of Cooper Companies in a report on Friday, January 9th. JPMorgan Chase & Co. raised their price target on shares of Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, December 5th. Weiss Ratings raised shares of Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. Finally, Barclays increased their price objective on shares of Cooper Companies from $98.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average price target of $90.79.

Cooper Companies Stock Down 3.4%

Shares of COO stock traded down $2.74 during trading hours on Friday, hitting $77.46. 1,933,102 shares of the company were exchanged, compared to its average volume of 1,998,570. The stock has a market capitalization of $15.11 billion, a price-to-earnings ratio of 41.20, a P/E/G ratio of 2.34 and a beta of 1.02. Cooper Companies has a one year low of $61.78 and a one year high of $89.83. The business’s 50-day simple moving average is $82.23 and its two-hundred day simple moving average is $75.95. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, March 5th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.07. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the prior year, the firm posted $0.92 earnings per share. Cooper Companies’s revenue for the quarter was up 6.2% compared to the same quarter last year. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Sell-side analysts predict that Cooper Companies will post 3.98 EPS for the current fiscal year.

Insider Transactions at Cooper Companies

In other news, Director Lawrence Erik Kurzius bought 2,000 shares of Cooper Companies stock in a transaction on Wednesday, December 17th. The stock was purchased at an average cost of $82.50 per share, with a total value of $165,000.00. Following the purchase, the director directly owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This trade represents a 34.62% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Cynthia L. Lucchese bought 1,784 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was purchased at an average price of $84.06 per share, with a total value of $149,963.04. Following the transaction, the director owned 9,445 shares in the company, valued at $793,946.70. The trade was a 23.29% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 16,014 shares of company stock worth $1,304,416 over the last 90 days. Corporate insiders own 2.08% of the company’s stock.

Institutional Trading of Cooper Companies

Several large investors have recently added to or reduced their stakes in COO. Root Financial Partners LLC grew its stake in shares of Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares in the last quarter. Bell Investment Advisors Inc lifted its holdings in Cooper Companies by 106.3% in the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after purchasing an additional 219 shares during the period. True Wealth Design LLC grew its position in Cooper Companies by 484.8% in the 4th quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock valued at $38,000 after buying an additional 383 shares in the last quarter. Cromwell Holdings LLC grew its position in Cooper Companies by 128.8% in the 4th quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock valued at $40,000 after buying an additional 273 shares in the last quarter. Finally, Board of the Pension Protection Fund acquired a new position in Cooper Companies during the 4th quarter valued at about $41,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 results beat on the bottom line and showed margin expansion (EPS $1.10 vs. consensus $1.03; revenue up ~6.2% year‑over‑year), which management said was driven by product momentum. Read More.
• Positive Sentiment: Company raised EPS and free‑cash‑flow guidance for 2026 and highlighted strength in MyDay and MiSight products — a constructive signal for longer‑term margin and cash conversion. Read More.
• Positive Sentiment: Multiple analysts reacted positively: Barclays bumped its target to $103 (overweight) and Needham raised its target to $101; William Blair reiterated a Buy on margin/portfolio confidence — these upgrades support upside potential. Read More.
• Neutral Sentiment: Research and investor‑education pieces (Zacks) emphasize COO’s growth attributes and style scores — useful context but not market‑moving by themselves. Read More.
• Neutral Sentiment: Company published its earnings call transcript and NCC research updates on lens wear — extra detail for diligence; unlikely to drive immediate moves absent new surprises. Read More. • Read More.
• Negative Sentiment: Shares declined intraday despite the beat — coverage noted sluggish core Vision growth and regional headwinds; some investors focused on revenue or segment softness rather than EPS strength. Read More.
• Negative Sentiment: At least one large shop (Morgan Stanley) remains cautious with a Hold and a lower target ($83), reflecting concerns that recovery in some end markets and core‑vision growth may be slower than peers expect. Read More.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.